亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

瑞士Evolva SA 
瑞士生物科技公司Evolva是一家專業研發治療動脈血栓形成以及真菌感染的公司。 而諾華投資（Novartis Venture）阿拉維（Aravis），太陽石資本（Sunstone Capita）以及丹麥創新資本集團（Dansk Innovations）都是其投資者之一。

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular our platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

We have used this platform across a range of pharmaceutical and related applications and have created a pipeline of strongly differentiated compounds that address major unmet medical needs. Our compounds are orally available, potent and cover new structural classes and/or new mechanisms. Our three most important compounds are:

EV-077 for renal disease and arterial thrombosis. EV-077 is in Phase I
EV-086 for fungal infections. EV-086 is in late pre-clinic
EV-075 for viral infections. EV-075 is in pre-clinic
In addition to our technology and compound assets, we pride ourselves on having an international business model that takes account of the new realities of biotech. One strand of this is the development of alliances that not only provide us with additional resources but also allow us to better understand the needs of current and future customers (whether corporations, doctors or patients). 2008 revenues (on a consolidated, IFRS basis) were c. CHF 12 million.

Our management team has a strong track record in building successful life science products and companies around the world. This is coupled with an internal culture that seeks to create, develop and improve innovative and value adding products and technologies.

We believe these four attributes – technology platform, products, business model and people – will stand Evolva in good stead going forward. Whilst any biotech company embodies a certain level of risk, Evolva has since its formation created a valuable and balanced portfolio of assets and programs that we believe provides a strong basis for future growth without undue risk.